Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v6-EN
Language English English
Date Updated 2020-03-21 2020-03-20
Drug Identification Number 00466085 00466085
Brand name M-M-R II M-M-R II
Common or Proper name (measles, mumps and rubella virus vaccine, live, attenuated) Lyophilized powder for injection (measles, mumps and rubella virus vaccine, live, attenuated) Lyophilized powder for injection
Company Name MERCK CANADA INC MERCK CANADA INC
Ingredients MUMPS VIRUS VACCINE LIVE ATTENUATED RUBELLA VIRUS VACCINE LIVE ATTENUATED MEASLES VIRUS VACCINE LIVE ATTENUATED MUMPS VIRUS VACCINE LIVE ATTENUATED RUBELLA VIRUS VACCINE LIVE ATTENUATED MEASLES VIRUS VACCINE LIVE ATTENUATED
Strength(s) 5000UNIT 1000UNIT 1000UNIT 5000UNIT 1000UNIT 1000UNIT
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 10X1DOSE VIAL 10X1DOSE VIAL
ATC code J07BD J07BD
ATC description VIRAL VACCINES VIRAL VACCINES
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2020-01-16 2020-01-16
Actual start date 2020-01-17 2020-01-17
Estimated end date 2020-03-27 2020-03-27
Actual end date 2020-03-20 2020-03-20
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Remaining doses are reserved for the public immunization program. /Les doses restantes sont réservées au programme public de vaccination. Remaining doses are reserved for the public immunization program. /Les doses restantes sont réservées au programme public de vaccination.
Health Canada comments